These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 29288941)
1. Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells. Ling Y; Guo J; Yang Q; Zhu P; Miao J; Gao W; Peng Y; Yang J; Xu K; Xiong B; Liu G; Tao J; Luo L; Zhu Q; Zhang Y Eur J Med Chem; 2018 Jan; 144():398-409. PubMed ID: 29288941 [TBL] [Abstract][Full Text] [Related]
2. β-Carboline tethered cinnamoyl 2-aminobenzamides as class I selective HDAC inhibitors: Design, synthesis, biological activities and modelling studies. Namballa HK; Anchi P; Lakshmi Manasa K; Soni JP; Godugu C; Shankaraiah N; Kamal A Bioorg Chem; 2021 Dec; 117():105461. PubMed ID: 34753060 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors. Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors. Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621 [TBL] [Abstract][Full Text] [Related]
5. Quinazoline-based hydroxamic acid derivatives as dual histone methylation and deacetylation inhibitors for potential anticancer agents. Zheng H; Dai Q; Yuan Z; Fan T; Zhang C; Liu Z; Chu B; Sun Q; Chen Y; Jiang Y Bioorg Med Chem; 2022 Jan; 53():116524. PubMed ID: 34847495 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors. Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008 [TBL] [Abstract][Full Text] [Related]
7. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects. Liao V; Liu T; Codd R Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors. Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122 [TBL] [Abstract][Full Text] [Related]
9. New aryldithiolethione derivatives as potent histone deacetylase inhibitors. Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity. Chetan B; Bunha M; Jagrat M; Sinha BN; Saiko P; Graser G; Szekeres T; Raman G; Rajendran P; Moorthy D; Basu A; Jayaprakash V Bioorg Med Chem Lett; 2010 Jul; 20(13):3906-10. PubMed ID: 20605448 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors. Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927 [TBL] [Abstract][Full Text] [Related]
13. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities. Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013 [TBL] [Abstract][Full Text] [Related]
14. 5-aryl-1,3,4-thiadiazole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents: synthesis, bioevaluation and docking study. Huong TT; Dung do TM; Oanh DT; Lan TT; Dung PT; Loi VD; Kim KR; Han BW; Yun J; Kang JS; Kim Y; Han SB; Nam NH Med Chem; 2015; 11(3):296-304. PubMed ID: 25256241 [TBL] [Abstract][Full Text] [Related]
15. Novel Pyridine-Based Hydroxamates and 2'-Aminoanilides as Histone Deacetylase Inhibitors: Biochemical Profile and Anticancer Activity. Zwergel C; Di Bello E; Fioravanti R; Conte M; Nebbioso A; Mazzone R; Brosch G; Mercurio C; Varasi M; Altucci L; Valente S; Mai A ChemMedChem; 2021 Mar; 16(6):989-999. PubMed ID: 33220015 [TBL] [Abstract][Full Text] [Related]
16. New benzothiazole/thiazole-containing hydroxamic acids as potent histone deacetylase inhibitors and antitumor agents. Tung TT; Oanh DT; Dung PT; Hue VT; Park SH; Han BW; Kim Y; Hong JT; Han SB; Nam NH Med Chem; 2013 Dec; 9(8):1051-7. PubMed ID: 23521008 [TBL] [Abstract][Full Text] [Related]
17. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer. Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548 [TBL] [Abstract][Full Text] [Related]
18. Discovery of potent histone deacetylase inhibitors with modified phenanthridine caps. Fan W; Zhang L; Wang X; Jia H; Zhang L J Enzyme Inhib Med Chem; 2021 Dec; 36(1):707-718. PubMed ID: 33663315 [TBL] [Abstract][Full Text] [Related]
19. Effect of phenylurea hydroxamic acids on histone deacetylase and VEGFR-2. Lee S; Wang SW; Yu CL; Tai HC; Yen JY; Tuan YL; Wang HH; Liu YT; Chen SS; Lee HY Bioorg Med Chem; 2021 Nov; 50():116454. PubMed ID: 34634618 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and evaluation of novel HDAC inhibitors as potential antitumor agents. Cheng J; Qin J; Guo S; Qiu H; Zhong Y Bioorg Med Chem Lett; 2014 Oct; 24(19):4768-4772. PubMed ID: 25182565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]